Xenon Pharmaceuticals (XENE) Total Debt (2017 - 2020)

Xenon Pharmaceuticals (XENE) has 4 years of Total Debt data on file, last reported at $15.7 million in Q1 2020.

• On a quarterly basis, Total Debt rose 3.55% year-over-year to $15.7 million in Q1 2020; TTM through Mar 2020 was $15.7 million, a 3.55% increase from a year earlier, with the FY2019 full-year figure at $15.5 million, up 3.5% from the prior year.
• Total Debt for Q1 2020 stood at $15.7 million, up from $15.5 million in the prior quarter.
• Over the last five years, Total Debt for XENE reached as high as $15.7 million in Q1 2020 and fell as low as $6.8 million in Q4 2017.
• Historically, Total Debt has averaged $13.2 million across 4 years, with a median of $15.1 million in 2018.
• Across the five-year window, Total Debt soared 120.66% in 2018 and climbed 3.47% in 2019, its largest moves.
• Year by year, Total Debt stood at $6.8 million in 2017, then surged by 120.66% to $15.0 million in 2018, then grew by 3.5% to $15.5 million in 2019, then advanced by 0.88% to $15.7 million in 2020.
• Per Business Quant data, the three most recent Total Debt figures were $15.7 million in Q1 2020, $15.5 million in Q4 2019, and $15.4 million in Q3 2019.